Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announces the change of its Chief Financial Officer. The current Chief Financial Officer of Heidelberg Pharma AG, Mr. Walter Miller, is leaving Heidelberg Pharma AG at his own request upon the expiration of his employment contract to pursue new professional challenges. Mr. Peter Willinger will assume the role of Chief Financial Officer effective 1 May 2026.
– CFO Walter Miller is leaving Heidelberg Pharma at the end of April
– Supervisory Board appoints Peter Willinger as a new Chief Financial Officer, effective 1 May 2026